The Vitamin D Receptor: The Key to Defeating Cancer?

YouTube, Sept 2026 11 minutes

Claude AI Summary

• (00:00–00:47) Focus on the vitamin D receptor (VDR) in pancreatic cancer. Researchers are looking at the VDR as a target in pancreatic ductal adenocarcinoma. Gene profiling showed the VDR is a key difference between activated cancer-associated fibroblasts and normal fibroblasts.

• (01:11–01:34) Cancer-associated fibroblasts (CAFs) help tumors grow. Activated CAFs release growth factors, collagen, and damaging molecules that support tumor growth. Switching them off could remove an important ally of the cancer.

• (02:00–02:48) VDR activation reduced CAF activation markers. In human trial data, activating the VDR lowered alpha-SMA clearly and FAP less clearly, compared with placebo.

• (02:48–03:36) Immune cells moved into the tumor. The same study found more immune cells infiltrating the tumor after VDR activation, which suggests a better anti-cancer immune response.

• (03:36–04:40) Tumors shrank in a phase 2 trial. Patients got the synthetic VDR agonist paricalcitol (oral or IV) on top of standard chemotherapy. Most showed some tumor shrinkage, and the effect was stronger and more consistent than with placebo. Not every patient responded.

• (05:03–05:32) Survival did not improve. Progression-free survival curves showed no separation between the paricalcitol and placebo groups, and other studies found the same.

• (05:53–07:28) Possible explanations for the mismatch:

  • Responders had higher VDR expression, so benefit may depend on receptor density, which could be tested in tumor biopsies.
  • The fixed dose of 75 mcg/week may have been too low. Small studies suggest dosing by body weight (7 mcg/kg) may work better.
  • The presenter speculates that gene editing could someday raise VDR density in tumors.

• (08:25–09:09) Observational data on natural vitamin D. Low blood vitamin D is generally linked to worse pancreatic cancer survival, though one study found no link. These studies are small, correlational, and prone to confounding.

• (09:31–10:33) Conclusions. The presenter thinks the evidence slightly favors vitamin D in two ways:

  • Keeping blood levels in the normal range, which he puts at above about 20 ng/mL, may help against pancreatic cancer.
  • Synthetic VDR agonists may become a future treatment.

• A clinical trial of vitamin D supplementation in pancreatic cancer is underway.

---

100+ items in Cancer + Vitamin D Receptor category in VitaminDWiki

• Cancer and the Vitamin D Receptor, a primer
• Risk of Cancer increased if poor Vitamin D Receptor – meta-analysis of 73 studies
• 8 Vitamin D Receptor activators can fight Pancreatic Cancer
• 9 to 50 cancers reduce Vitamin D receptor activation
• Pancreatic Cancer protects itself deactivating HNF4A (which can be reactivated by the Vitamin D Receptor)
• Vitamin D Receptor (Cancers OR Viruses) - many studies
• Blood cell cancer is associated with a 3X worse Vitamin D Receptor
• The Role of Resveratrol in Cancer Therapy
• Vitamin D Receptor deactivated by some health problems - many studies
• Women with Breast Cancer were 16.9 times more likely to have a poor Vitamin D Receptor
  Reminder: BC protects itself by reducing VDR activation